CB 001 - Ceronco Biosciences

Drug Profile

CB 001 - Ceronco Biosciences

Alternative Names: CB-001 - Ceronco Biosciences; Doxorubicin liposomal - Ceronco Biosciences; GC enriched liposomal doxorubicin - Ceronco Biosciences; Glucosylceramide enriched doxorubicin - Ceronco Biosciences

Latest Information Update: 26 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ceronco Biosciences
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ovarian cancer; Soft tissue sarcoma

Most Recent Events

  • 26 Oct 2016 Preclinical trials in Ovarian cancer in Netherlands (unspecified route)
  • 26 Oct 2016 Preclinical trials in Soft tissue sarcoma in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top